E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI, professor of medicine at Duke University Medical Center, discussed the results of the GEMINI-ACS-1 trial comparing rivaroxaban and aspirin in acute coronary syndrome (ACS), which he and his co-authors presented at the American College of Cardiology 66th Scientific Session. They found no significant differences in the primary endpoints and ischemic outcomes, though further research will be necessary to inform clinical practice.